Health Canada approves Pfizer-BioNTech’s updated COVID-19 vaccine
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. Packaging for the Pfizer's updated COVID vaccine for ages 12 and up is shown in an August 2024 handout photo.
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and
Pfizer and BioNTech’s Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive EU Opinion, Awaiting Approval
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA)
BioNTech SE ADR rises Monday, outperforms market
The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
BioNTech SE (BNTX) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...
Pharmaceutical Technology16h
BioNTech gets grant for rna lipoplex particles for targeted delivery and storage
Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
Forecasting The Future: 8 Analyst Projections For BioNTech
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
CTV News5m
Manitoba unveils plan to lower age for mammogram self-referrals
The province has announced a new plan to lower the age for mammogram self-referrals to 40 from 50 in an effort to get more ...
Hosted on MSN6d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit ...